Cargando…
1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models
Introduction: We aimed to evaluate the influence of 1,25-dihydroxyvitamin D (1,25(OH)(2)D) on metabolic dysfunction and elucidate its underlying mechanism using a rat model of polycystic ovary syndrome (PCOS). Methods: Twenty-four Sprague-Dawley rats were randomly divided into four groups: control g...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136241/ https://www.ncbi.nlm.nih.gov/pubmed/37124226 http://dx.doi.org/10.3389/fphar.2023.1077014 |
_version_ | 1785032170474045440 |
---|---|
author | Yuan, Xin Yang, Jianshu Sun, Danlin Luo, Kaiming Jiang, Xiaohong Wang, Long Xiang, Shoukui Jiang, Yijie Ge, Kele Zhou, Zhiyang Li, Bowen Hua, Fei |
author_facet | Yuan, Xin Yang, Jianshu Sun, Danlin Luo, Kaiming Jiang, Xiaohong Wang, Long Xiang, Shoukui Jiang, Yijie Ge, Kele Zhou, Zhiyang Li, Bowen Hua, Fei |
author_sort | Yuan, Xin |
collection | PubMed |
description | Introduction: We aimed to evaluate the influence of 1,25-dihydroxyvitamin D (1,25(OH)(2)D) on metabolic dysfunction and elucidate its underlying mechanism using a rat model of polycystic ovary syndrome (PCOS). Methods: Twenty-four Sprague-Dawley rats were randomly divided into four groups: control group (CON, 2 ml/kg of oral 0.5% CMC), 1,25VD group (oral 0.5% CMC and 2.5 ug/kg intraperitoneal 1,25(OH)(2)D), PCOS group (1 mg/kg oral letrozole), PCOS+1,25VD group (1 mg/kg oral letrozole orally 2.5 ug/kg intraperitoneal 1,25(OH)(2)D). The treatments were administered for 8 weeks. Body weight, estrus cycle, insulin tolerance, and oral glucose tolerance of the rats in the different groups were assessed. The rats were euthanized at the 8th weeks, and plasma, ovarian, and liver samples were collected and analyzed. The hepatic lipid profile was characterized using HPLC/MRM. Results: Letrozole-induced PCOS rats exhibited increased weight, insulin resistance, postprandial glucose abnormalities, and dyslipidemia. Compared with the PCOS group rats, the PCOS+1,25VD group rats showed reduced body weight, increased sensitivity to insulin, decreased postprandial glucose, and elevated levels of high-density lipoprotein cholesterol. Moreover, abnormally increased liver concentrations of total diacylglycerol (DG) and DG species in the PCOS rats were reversed by treatment with 1,25(OH)(2)D. Additionally, hepatic DG and insulin sensitivity were correlated. Conclusion: 1,25(OH)(2)D inhibited hepatic DG accumulation and ameliorated metabolic dysfunction in PCOS rat models. |
format | Online Article Text |
id | pubmed-10136241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101362412023-04-28 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models Yuan, Xin Yang, Jianshu Sun, Danlin Luo, Kaiming Jiang, Xiaohong Wang, Long Xiang, Shoukui Jiang, Yijie Ge, Kele Zhou, Zhiyang Li, Bowen Hua, Fei Front Pharmacol Pharmacology Introduction: We aimed to evaluate the influence of 1,25-dihydroxyvitamin D (1,25(OH)(2)D) on metabolic dysfunction and elucidate its underlying mechanism using a rat model of polycystic ovary syndrome (PCOS). Methods: Twenty-four Sprague-Dawley rats were randomly divided into four groups: control group (CON, 2 ml/kg of oral 0.5% CMC), 1,25VD group (oral 0.5% CMC and 2.5 ug/kg intraperitoneal 1,25(OH)(2)D), PCOS group (1 mg/kg oral letrozole), PCOS+1,25VD group (1 mg/kg oral letrozole orally 2.5 ug/kg intraperitoneal 1,25(OH)(2)D). The treatments were administered for 8 weeks. Body weight, estrus cycle, insulin tolerance, and oral glucose tolerance of the rats in the different groups were assessed. The rats were euthanized at the 8th weeks, and plasma, ovarian, and liver samples were collected and analyzed. The hepatic lipid profile was characterized using HPLC/MRM. Results: Letrozole-induced PCOS rats exhibited increased weight, insulin resistance, postprandial glucose abnormalities, and dyslipidemia. Compared with the PCOS group rats, the PCOS+1,25VD group rats showed reduced body weight, increased sensitivity to insulin, decreased postprandial glucose, and elevated levels of high-density lipoprotein cholesterol. Moreover, abnormally increased liver concentrations of total diacylglycerol (DG) and DG species in the PCOS rats were reversed by treatment with 1,25(OH)(2)D. Additionally, hepatic DG and insulin sensitivity were correlated. Conclusion: 1,25(OH)(2)D inhibited hepatic DG accumulation and ameliorated metabolic dysfunction in PCOS rat models. Frontiers Media S.A. 2023-04-05 /pmc/articles/PMC10136241/ /pubmed/37124226 http://dx.doi.org/10.3389/fphar.2023.1077014 Text en Copyright © 2023 Yuan, Yang, Sun, Luo, Jiang, Wang, Xiang, Jiang, Ge, Zhou, Li and Hua. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yuan, Xin Yang, Jianshu Sun, Danlin Luo, Kaiming Jiang, Xiaohong Wang, Long Xiang, Shoukui Jiang, Yijie Ge, Kele Zhou, Zhiyang Li, Bowen Hua, Fei 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
title | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
title_full | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
title_fullStr | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
title_full_unstemmed | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
title_short | 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
title_sort | 1,25-dihydroxyvitamin d inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136241/ https://www.ncbi.nlm.nih.gov/pubmed/37124226 http://dx.doi.org/10.3389/fphar.2023.1077014 |
work_keys_str_mv | AT yuanxin 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT yangjianshu 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT sundanlin 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT luokaiming 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT jiangxiaohong 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT wanglong 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT xiangshoukui 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT jiangyijie 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT gekele 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT zhouzhiyang 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT libowen 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels AT huafei 125dihydroxyvitamindinhibitshepaticdiacyglycerolaccumulationandamelioratesmetabolicdysfunctioninpolycysticovarysyndromeratmodels |